A Study of SHR6508 in Secondary Hyperparathyroidism

NCT05663411 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG: SHR6508
DRUG: SHR6508
DRUG: Cinacalcet

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.